Subscribe

Shitanshu Uppal

Publications Update # 107

A discussion on how to cure loneliness in the US, Phase 2 trial - Most Circuit - Ipi/Nivo in clear cell cancer, camrelizumab and Famitinb in cervical cancer, impact of prior radiation on immunotherapy drugs, and HRT in young patients.

Camrelizumab and Famitinib in Cervical Cancer - Phase 2 Trial

Camrelizumab plus famitinib significantly improves response rate and survival outcomes compared to camrelizumab alone or chemotherapy in pretreated R/M CC with a manageable safety profile.

Publications Update # 106

MAPK/FAK Clamp - RAMP 201 Avutomentinib and Defactinib in Low Grade Ovarian, IP chemotherapy question, ROSELLA Trial and PROFECTA-II Trial, Palliative Oophorectomy in gastric cancers

GOG 3073/ENGOT-72: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA)

Relacorilant plus nab-paclitaxel significantly prolonged PFS and showed a clinically meaningful interim OS improvement versus nab-paclitaxel alone, with manageable toxicity, positioning the combination as a potential new standard for platinum-resistant ovarian cancer.

Publications Update # 105

Making magic with Brad Meltzer, venous thromboembolism during ambulatory chemotherapy in endometrial cancer (including the NCCN and ASCO guidelines), IMRT in vulvar cancer, and hypofractionated adjuvant radiation in cervical cancer patients.

Publications Update # 104

New Episode of GYOEDU Podcast, ASCO abstracts - Challenge trial, TRUST trial, cytoxan+Avastin vs. cytoxan+Avastin+Pembrolizumab, Menopause management with Elinzatenant, and a review of cancer of unknown primary site.

Publications Update # 103

MIS in cervical cancer in SHAPE trial-eligible patients, pragmatic testing with IHC rather to replace the PROMISE algorithm and two questions about PFT and vulvar cancer groin management.

Congratulations, and No Newsletter this week

SOLO-3: Olaparib vs. Chemotherapy in PSROC

Olaparib significantly improved PFS and ORR over nonplatinum chemotherapy, though no OS benefit was observed in the overall population. In patients with ≥3 prior therapies, chemotherapy had more favorable OS.

Question of the Day 05-21-25

Which of the following best characterizes the drug-to-antibody ratio (DAR)